Altimmune, Inc.
HealthcareNASDAQ:ALT · NASDAQ Global Market
+$0.02 today
Vol 2.08M · Avg 3.81M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-39.2%
avg 43.3%
ROIC
-35.4%
avg -49.7%
ROA
-31.5%
avg -32.8%
Analysis
ROA is currently the strongest return metric at -31.5% versus its period average of -32.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Scot Roberts | Chief Scientific Officer | $683,229.00 | — | 67 | $95,430.00 | 0.11% |
Gregory L. Weaver | Chief Financial Officer | $619,694.00 | — | 70 | $38,078.00 | 0.04% |
Raymond Jordt | Chief Business Officer | $578,850.00 | — | 53 | $70,107.00 | 0.08% |
Christophe Arbet-Engels | Chief Medical Officer | $361,356.00 | — | 63 | $150,000.00 | 0.17% |
Jerome Benedict Durso | Chairman, CEO & President | $50,941.00 | — | 58 | $47,500.00 | 0.05% |
Andrew Shutterly | Principal Financial & Accounting Officer and Corporate Controller | — | — | 38 | $11,372.00 | 0.01% |
Bertrand Georges | Chief Technology Officer | — | — | — | — | — |
Tony Blandin | Vice President of Quality & Compliance Management | — | — | — | — | — |
Robin E. Abrams | Chief Legal Officer & Corporate Secretary | — | — | 62 | — | — |
Linda Richardson | Chief Commercial Officer | — | — | 62 | $96,000.00 | 0.11% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
10
$325,787.82
Sells
0
$0.00
Net Sentiment
+$325,787.82
Net buying
Most Active
Durso Jerome Benedict
3 transactions
Analysis
Insiders reported 10 buys worth $325,787.82 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $325,787.82. Durso Jerome Benedict was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | -25.0% | +20.4% (15yr)7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Recent growth has been strongest in Revenue at -25.0% over three years. Forward estimates point to Revenue at +20.4% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
$814.99M
Alto Neuroscience, Inc.
NYSE:ANRO
$753.47M
Annexon, Inc.
NASDAQ:ANNX
$563.29M
DBV Technologies S.A.
NASDAQ:DBVT
$416.60M
Aura Biosciences, Inc.
NASDAQ:AURA
$411.52M
Amarin Corporation plc
NASDAQ:AMRN
$315.21M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$296.96M
AC Immune S.A.
NASDAQ:ACIU
$235.10M
Korro Bio, Inc.
NASDAQ:KRRO
$115.56M
enGene Holdings Inc.
NASDAQ:ENGN
$82.94M
Who manages ALT?
Altimmune, Inc. (ALT) lists 10 active executives. The top listed executive is Andrew Shutterly, Principal Financial & Accounting Officer and Corporate Controller.
Are ALT insiders buying or selling?
Recent insider activity shows net buying of $27.36M.
Explore More
Continue the stock analysis
Jump to another research area for this company.